We thank Christopher Locher (Vertex Pharmaceuticals) and Omar Vandal (Bill & Melinda Gates Foundation) for discussions of M. tuberculosis targets, and Clifton Barry (National Institute of Allergy and Infectious Diseases), Michael Crawford (Divergence), David Fidock (Columbia University), Timothy Geary (McGill University), James McCarter (Divergence), Geoff McFadden (University of Melbourne), Samuel Sia (Columbia University), and Mark Schreiber (Novartis Institute for Tropical Diseases) for input on target selection strategies.